Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.

Protein science : a publication of the Protein Society - 1 Sept 2002

Kokoris Mark S, Black Margaret E

Abstract excerpt

Herpes Simplex Virus type 1 (HSV-1) thymidine kinase (TK) is currently the most widely used suicide agent for gene therapy of cancer. Tumor cells that express HSV-1 thymidine kinase are rendered sensitive to prodrugs due to preferential phosphorylation by this enzyme. Although ganciclovir (GCV) is the prodrug of choice for use with TK, this approach is limited in part by the toxicity of this prodrug. From a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acyclovir
Share to Chromatography, Affinity

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Ganciclovir

Share to Genetic Therapy

Share to Herpesvirus 1, Human

Share to Molecular Structure

Share to Prodrugs

Share to Thymidine Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 12192082
DOI: 10.1110/ps.2460102
PMCID: PMC2373606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.PMID 12192082Read ↗

Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.Semantic proximity Read ↗

Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.Semantic proximity Read ↗

Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies.Semantic proximity Read ↗

Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants.Semantic proximity Read ↗

Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.Semantic proximity Read ↗

Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities.Semantic proximity Read ↗

A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing.Semantic proximity Read ↗

Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation.Semantic proximity Read ↗

Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase.Semantic proximity Read ↗

Mutations distal to the substrate site can affect varicella zoster virus thymidine kinase activity: implications for drug design.Semantic proximity Read ↗

Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: analysis of selected mutants in vitro.Semantic proximity Read ↗

Systematic exploration of active site mutations on human deoxycytidine kinase substrate specificity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.